Germany · Delayed Price · Currency is EUR Avecho Biotechnology Statistics
Total Valuation
FRA:OEZ has a market cap or net worth of EUR 20.70 million. The enterprise value is 17.39 million.
| Market Cap | 20.70M |
| Enterprise Value | 17.39M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 3.67B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +9.80% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 23.50% |
| Owned by Institutions (%) | 3.57% |
| Float | 2.57B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.86 |
| PB Ratio | 44.94 |
| P/TBV Ratio | 44.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 31.12 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.60 |
| EV / Sales | 22.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.62 |
| Quick Ratio | 4.46 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29.15 |
Financial Efficiency
Return on equity (ROE) is -143.71% and return on invested capital (ROIC) is -83.61%.
| Return on Equity (ROE) | -143.71% |
| Return on Assets (ROA) | -33.53% |
| Return on Invested Capital (ROIC) | -83.61% |
| Return on Capital Employed (ROCE) | -61.87% |
| Revenue Per Employee | 51,380 |
| Profits Per Employee | -134,827 |
| Employee Count | 15 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 4.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.86% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +42.86% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 91.73 |
| Average Volume (20 Days) | 2,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:OEZ had revenue of EUR 770,695 and -2.02 million in losses. Loss per share was -0.00.
| Revenue | 770,695 |
| Gross Profit | 479,890 |
| Operating Income | -1.96M |
| Pretax Income | -2.02M |
| Net Income | -2.02M |
| EBITDA | -1.88M |
| EBIT | -1.96M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 3.31 million in cash and 31,889 in debt, giving a net cash position of 3.28 million.
| Cash & Cash Equivalents | 3.31M |
| Total Debt | 31,889 |
| Net Cash | 3.28M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 460,646 |
| Book Value Per Share | 0.00 |
| Working Capital | 3.09M |
Cash Flow
| Operating Cash Flow | 665,227 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 62.27%, with operating and profit margins of -253.71% and -262.41%.
| Gross Margin | 62.27% |
| Operating Margin | -253.71% |
| Pretax Margin | -262.41% |
| Profit Margin | -262.41% |
| EBITDA Margin | -243.67% |
| EBIT Margin | -253.71% |
| FCF Margin | n/a |
Dividends & Yields
FRA:OEZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.80% |
| Shareholder Yield | -9.80% |
| Earnings Yield | -9.77% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:OEZ has an Altman Z-Score of -52.35 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -52.35 |
| Piotroski F-Score | 5 |